Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

449
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
449
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

15.4K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
15.4K
Introduction to Hemostasis01:05

Introduction to Hemostasis

15.8K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
15.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Taipan snake venom time has high sensitivity for lupus anticoagulants in non-anticoagulated, triple positive antiphospholipid syndrome patients.

International journal of laboratory hematology·2024
Same author

Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay.

Journal of thrombosis and haemostasis : JTH·2023
Same author

Post-operative of bleeding, haemolysis and coagulation in mechanical circulatory support patients.

Annals of translational medicine·2020
Same author

Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.

Blood·2019
Same author

Hb Penang [β78(EF2)Leu→Pro, HBB: c.236T>C]: a Novel β-Globin Variant.

Hemoglobin·2018
Same author

Heparin-Induced Thrombocytopenia and Vascular Surgery.

Journal of cardiothoracic and vascular anesthesia·2017
Same journal

The Distribution of Kell Blood Group Antigens and Phenotypes (K and K) Among Saudi Blood Donors of King Abdulaziz Medical City - Western Region: A Cross-Sectional Study.

Journal of blood medicine·2026
Same journal

A Delphi Consensus by Hematologists on the Burden of Treatment on Patients with Severe Hemophilia in Mexico.

Journal of blood medicine·2026
Same journal

A Clinical Investigation of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies and Burns.

Journal of blood medicine·2026
Same journal

ATG Plus Post-Transplantation Cyclophosphamide Improves EBV-DNA Clearance and GVHD in Patients of Adult Chronic Active Epstein-Barr Virus Disease Undergoing Allogeneic HSCT.

Journal of blood medicine·2026
Same journal

Care Patterns, Outcomes, and Costs in Peripheral T-Cell Lymphoma Patients with First-Line Treatment in Routine Clinical Practice in Europe.

Journal of blood medicine·2026
Same journal

Malignancy-Associated Hemophagocytic Lymphohistiocytosis: An Experience of 15 Years in Polish Pediatric Hematology Centers.

Journal of blood medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 14, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

12.1K

Acquired hypofibrinogenemia: current perspectives.

Martin W Besser1, Stephen G MacDonald2

  • 1Department of Haematology.

Journal of Blood Medicine
|October 8, 2016
PubMed
Summary
This summary is machine-generated.

Aggressively replacing fibrinogen is key for massive hemorrhage. This review compares lab and point-of-care methods for measuring fibrinogen levels, aiding treatment decisions in acquired hypofibrinogenemia.

Keywords:
Clauss fibrinogen assayPT-derived fibrinogenafibrinogenemiadirect oral anticoagulantdysfibrinogenemiafibrinogen antigenfunctional fibrinogengravimetric fibrinogen assayviscoelastic testing

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.3K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Related Experiment Videos

Last Updated: Mar 14, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

12.1K
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.3K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Area of Science:

  • Hematology
  • Clinical Pathology
  • Critical Care Medicine

Background:

  • Acquired hypofibrinogenemia often results from hemodilution and clotting factor consumption.
  • Fibrinogen replacement is a cornerstone in managing massive hemorrhage.
  • Accurate fibrinogen quantification is crucial, especially in acquired dysfibrinogenemia, impacting therapeutic choices.

Approach:

  • This review synthesizes current knowledge on fibrinogen measurement techniques.
  • It evaluates both laboratory-based assays and point-of-care (POC) testing methods.
  • Advantages and limitations of each method are discussed in the context of clinical application.

Key Points:

  • The optimal method for determining fibrinogen levels in acquired hypofibrinogenemia is debated.
  • Different quantification methods can lead to significant variations in therapeutic decisions.
  • Understanding assay performance is vital for effective patient management.

Conclusions:

  • This review provides an overview of available fibrinogen quantification methods.
  • It highlights the importance of selecting appropriate assays for guiding fibrinogen replacement therapy.
  • Strategies for correcting hypofibrinogenemia are discussed based on current evidence.